Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasms by Cortés, Alicia Arenas et al.
haematologica | 2019; 104(5) 937
Received: July 10, 2018.
Accepted: December 10, 2018.
Pre-published: December 13, 2018.
©2019 Ferrata Storti Foundation
Material published in Haematologica is covered by copyright.
All rights are reserved to the Ferrata Storti Foundation. Use of
published material is allowed under the following terms and
conditions: 
https://creativecommons.org/licenses/by-nc/4.0/legalcode. 
Copies of published material are allowed for personal or inter-
nal use. Sharing published material for non-commercial pur-
poses is subject to the following conditions: 
https://creativecommons.org/licenses/by-nc/4.0/legalcode,
sect. 3. Reproducing and sharing published material for com-









Check the online version for the most updated
information on this article, online supplements,
and information on authorship & disclosures:
www.haematologica.org/content/104/5/937
Ferrata Storti Foundation
Ruxolitinib is the front-line non-palliative treatment for myelofibro-sis (MF). However, a significant number of patients lose or presentsuboptimal response, are resistant or have unacceptable toxicity.
In an attempt to improve response and avoid the adverse effects of this
drug, we evaluated the combination of 17 drugs with ruxolitinib in 
ex vivo models of peripheral blood mononuclear cells from MF patients
and cell lines. We found that the combination ruxolitinib and nilotinib
had a synergistic effect against MF cells (ΔEC50 nilotinib, -21.6%).
Moreover, the addition of prednisone to combined ruxolitinib/nilotinib
improved the synergistic effect in all MF samples studied. We evaluated
the molecular mechanisms of combined  ruxolitinib/nilotinib/pred-
nisone and observed  inhibition of JAK/STAT (STAT5, 69.2+11.8% inhi-
bition) and MAPK (ERK, 29.4+4.5% inhibition) signaling pathways.
Furthermore, we found that the triple therapy combination inhibited
collagen protein and COL1A1 gene expression in human bone marrow
mesenchymal cells. Taken together, we provide evidence that combined
ruxolitinib/nilotinib/prednisone is a potential therapy for MF, possibly
through the anti-fibrotic effect of nilotinib, the immunomodulatory
effect of ruxolitinib and prednisone, and the anti-proliferative effect of
ruxolitinib. This combination will be further investigated in a phase Ib/II
clinical trial in MF.
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Myelofibrosis (MF) is a Philadelphia chromosome-negative chronic myeloprolif-
erative neoplasm (MPN) clinically characterized by stem cell-derived clonal myelo-
proliferation and a reactive cytokine-driven increase in bone marrow (BM)
fibrosis.1,2 Patients with MF have a poor prognosis and a median survival of 5.8
years.1
Dysregulation of JAK/STAT signaling is the main cause of MPN and, accordingly,
inhibitors of the JAK/STAT signal transduction pathway are currently the best clin-
ical approach to treat this disease. Discovered in 2005,3-7 a mutation in the JAK2
gene resulting in a substitution of valine for phenylalanine (V617F) was found in
approximately 90% of patients with polycythemia vera (PV), and in 50-60% of
patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF).8
In addition, mutations in the MPL gene, which encodes the thrombopoietin recep-
tor, were found in approximately 1% of patients with MPN,9 and 12% of patients
with MPN (35-50% of MF) have mutations in calreticulin (CALR).10-12 Interestingly,
the mutated forms of CALR acquire the ability to activate the thrombopoietin
receptor and, therefore, constitutively activate the
JAK/STAT pathway.13,14 
Ruxolitinib, a JAK1/JAK2 inhibitor, is the first and only
drug approved by the European Medicines Agency for the
treatment of PMF, post-PV MF, and post-ET MF15 and is
the first-line treatment for MF. Results of the COMFORT-
I and II clinical trials showed that ruxolitinib produced a
reduction in spleen volume, improved MF-related symp-
toms, and was associated with prolonged overall survival
of patients compared with controls.15
Despite the beneficial effect of ruxolitinib, a high per-
centage of patients lose their response at some point dur-
ing treatment, and others are refractory or present a sub-
optimal response. Because of this, the use of drug combi-
nations might increase the effectiveness of the treatment
and response time, and overcome treatment resistance.
Indeed, numerous studies have used this premise, and a
number of combinations have been tested in clinical trials
with varying success. For instance, whereas the combina-
tion of ruxolitinib with simtuzumab (clinicaltrials.gov iden-
tifier: 01369498) produced no clinical benefit,16 and the
combination with lenalidomide (clinicaltrials.gov identifier:
01375140) had to be terminated early because the efficacy
objectives were not achieved,17 the combination with
danazol (clinicaltrials.gov identifier: 01732445) achieved a
hematologic stabilization but did not increase the
response to ruxolitinib.18 Other combinations including
ruxolitinib with buparlisib (clinicaltrials.gov identifier:
01730248) or with panobinostat (clinicaltrials.gov identifiers:
01693601 and 01433445) are currently under evaluation in
clinical trials. In this scenario, the objective of the present
study was to develop a drug combination that enhances
the effect of ruxolitinib in the treatment of MF. 
The proposed combination in this work, ruxolitinib,
nilotinib and prednisone, is the result of  testing 17 drugs
with ruxolitinib to evaluate the best therapy for MF. We
hypothesized that this combination would be synergic
through a decrease in the proinflammatory status by rux-
olitinib and prednisone19 and the known antifibrogenic
effect of nilotinib,20 and would result in a better histologi-
cal response. 
Methods
Primary samples and cell lines
Peripheral blood (PB) samples were collected from MF patients
and from healthy donors after obtaining informed consent in
accordance with the guidelines of the 12 Octubre Hospital ethics
committee and the Declaration of Helsinki. The diagnosis of MF
was based on 2016 World Health Organization criteria.21 PB
mononuclear cells (PBMCs) were isolated from 6-10 mL of PB by
density gradient centrifugation (Ficoll-Paque™ PLUS, GE
Healthcare, Little Chalfont, UK) and were cultured (0.4x106
cells/mL) in Methocult TM GF_H4535 supplemented with 20
ng/mL IL-3 and 50 ng/mL Stem Cell Factor (both from StemCell
Technologies, Vancouver, Canada) at 37°C in a humidified atmos-
phere containing 5% CO2. For the drug screening study, samples
from 9 patients were used; age range was 49-83 years, there were
5 males and 4 females, and 6 of them harbored the JAK2-V617F
mutation (Online Supplementary Table S1). For synergy studies, all
patients (aged 66-83 years) had the JAK2-V617F mutation (3 males
and 2 females). No patient had been treated previously (Online
Supplementary Table S2).
The BA/F3 wild-type (BA/F3 WT), BA/F3 with JAK2-V617F
mutation (BA/F3 V617F JAK2), and WEHI cell lines were kindly
provided by Dr Quintás-Cardama (MD Anderson Cancer Center,
Houston, TX, USA). The WEHI cell line, which produces IL-3, was
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM)
(Biowest, Nuaillé, France) with 10% heat-inactivated fetal bovine
serum (FBS). BA/F3 cells were cultured in Roswell Park Memorial
Institute (RPMI) 1640 medium (Biowest, Nuaillé, Francia) with
10% FBS plus 10% conditioned medium from WEHI cells. The
SET2 cell line (DSMZ, Braunschweig, Germany), which harbors
the JAK2-V617F mutation, was cultured in RPMI 1640 with 20%
FBS. The HS27a human BM mesenchymal cell line (DSMZ) was
cultured in DMEM with 10% FBS. 
Dose response and synergy analysis
A total of 10,000-20,000 cells of the different cell lines were
seeded per well in 96-well plates in the presence of the drugs alone
(Table 1 and Online Supplementary Table S3) or in combination with
ruxolitinib. Dimethyl sulfoxide (DMSO) was used as vehicle.
After 48-72 hours (h), cell viability was measured by flow cytom-
etry with Annexin V-phycoerythrin (Biolegend, San Diego, CA,
USA) or the metabolic WST-8 assay (Cell Counting Kit - 8
BioChemika; Sigma-Aldrich). Drugs were purchased from Sigma-
Aldrich (St. Louis, MO, USA), Tocris (Bristol, UK) or kindly donat-
ed by Novartis (Basel, Switzerland). 
Peripheral blood mononuclear cells were treated as follows: a)
directly delivering the drugs to methylcellulose solid culture at the
outset of the experiment (ex vivo, model A); or b) after 14 days of
methylcellulose culture (ex vivo, model B). In model B, colony-
forming cells were collected, washed with phosphate buffer saline
(PBS) and cultured in RPMI with 10% FBS at 15,000 cells per well
in 96-well plates in the presence of the drugs alone (Table 1) or in
combination with ruxolitinib, for 72 h. DMSO was used as vehicle
at a maximum concentration of 0.5%. Flow cytometry to measure
myeloid cell viability was performed with monoclonal antibodies
against CD45-allophycocyanin-Cy7, CD13-allophycocyanin and
Annexin V-phycoerythrin (all from Biolegend, San Diego, CA,
USA) using the ExviTech automated flow cytometry plataform.
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Table 1. Drugs used in the screening to search for the best combination
with ruxolitinib.
Drug                                                               Target
Ruxolitinib                                                         Jak 1/2 inhibitor 
Nilotinib                                          PDGF-R. c-kit and BCR/ABL inhibitor
Bosutinib                                                    Src/Abl kinase inhibitor
Ponatinib                                                         BCR/ABL inhibitor
Midostaurin                                                        FLT3 inhibitor
Sorafenib                                                      Multikinase inhibitor
Buparlisib                                                            PI3K inhibitor
Dactolisib                                                  PI3K/Akt/mTOR inhibitor
Everolimus                                                        mTOR inhibitor
Sonidegib                                                            SMO inhibitor
SB 431542                                               Inhibitor of TGF-β receptor
LCL161                                                                 SMAC mimetic
Bortezomib                                                  Proteosome inhibitor
Panobinostat                                        Deacetylase histone inhibitor
HSP990                                                               HSP90 inhibitor
Prednisone                                                   Immunosuppressant
Anagrelide                                               PDE3 immunosuppressant
Danazol                                   Antigonadotropic and anti-estrogenic activity
Collagen I expression study
Hs27a cells were treated with 100 nM ruxolitinib, 1 mM nilo-
tinib or 1 mM prednisone or their combinations for 1 h.
Subsequently, 2 ng/mL of TGF-β (R&D Systems, Minneapolis,
MN, USA) was added and cells were incubated for a further 24 h.
Immunocytochemistry and quantitative polymerase chain reac-
tion (qPCR) analysis was used to measure collagen I expression.
Protein array and western blotting
The effects of 32 nM ruxolitinib, 1.6 mM nilotinib, 0.8 mM pred-
nisone and their combinations, on protein phosphorylation were
analyzed using the Human Phospho-kinase Array (Proteome
ProfilerTM, R&D Systems) and by western blotting. Antibodies
against phosphorylated or non-phosphorylated STAT5 and ERK
1/2 proteins (Cell Signaling Technology, Danvers, MA, USA) were
used in western blotting analysis. Tubulin was used as a loading
control and was purchased from Abcam (Cambridge Science Park,
Cambridge, UK). Proteins were visualized with the ChemiDoc
MP imaging system (BioRad laboratories, Hercules, CA, USA),
quantified, corrected for housekeeping expression, and normal-
ized to control samples using the ImageLab software program
(v.5.1, BioRad).
Quantitative polymerase chain reaction 
Total RNA was prepared with the AllPrepTM DNA/RNA Micro
Kit (Qiagen, Hilden, Germany). Reverse transcription reaction was
carried out using the High Capacity cDNA Reverse Transcription
Kit system (Life Technologies, Carlsbad, MA, USA). Real-time
PCR was performed with Taqman Gene Expression Master Mix
and gene-specific Taqman probe COL1A1 (Hs00164004_m1)
using the 7900HT Fast Real-Time PCR Systems platform (all from
Life Technologies). Normalized gene expression levels were calcu-
lated using GAPDH mRNA expression as a housekeeping gene.
Immunocytochemistry
HS27a cells were fixed with 4% paraformaldehyde (Merck
Millipore, Billerica, MA, USA) permeabilized and blocked with
0.25% Triton X-100 plus 1% BSA in PBS for 30 minutes (min).
Slides were incubated with antibodies against collagen I (Abcam)
for one hour, followed by a 5-min incubation with 3% H2O2 to
inactivate endogenous peroxidase. After incubation with a perox-
idase-conjugated secondary antibody for 1 h, signals were
revealed with 3,3 diaminobenzidine (Abcam). Counterstaining
was performed with Carazzi's hematoxylin (AppliChem Panreac,
Darmstadt, Germany). Images were visualized on the Eclipse 80i
(Nikon) microscope equipped with a DS-Fi1 camera (Nikon,
Minato, Tokyo, Japan). Stained areas were calculated with ImageJ
(Rasband, W.S., ImageJ, NIH, Bethesda, MD, USA).
Statistical analysis 
The analysis of drug dose-response was performed using the
non-linear regression model (Equation 1):
E=E0+Emax−E01+ 10(logEC50−C)
where C is the drug concentration; E is the drug effect; Emax,
the maximum drug efficacy in terms of survival; E0, survival when
only DMSO is applied; EC50, drug concentration in which 50% of
the total drug action is achieved; and γ the slope of the curve. The
area under curve (AUC) of dose response curves was also calculat-
ed.
The study of the behavior of drugs in combination was per-
formed using ΔEC50, the percentage of difference between EC50 of
each drug in combination with ruxolitinib minus their EC50 in
monotherapy.
Synergy analysis was performed using Calcusyn v.2.0 (Biosoft,
Ferguson, MO, USA). The calculations performed by the program
are based on the median-effect equation formulated by Chou.22
The combination index (CI) is the parameter by which the syner-
gy or antagonism of two drugs were quantified (Equation 2):
𝐶𝐼= 𝐶𝐷𝐶𝐷|𝑅+𝐶𝑅𝐶𝑅|𝐷
where CD is the concentration of each drug, CR is the ruxolitinib
concentration, and  is the concentration of a drug in the presence
of another drug that causes a certain effect. A CI <0.8 indicates
synergism. 
Shapiro-Wilk and Levene’s robust test statistic were applied to
evaluate normality and homoscedasticity, respectively. Linear
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Table 2. Results of the dose-response curves of drugs in monotherapy in patients' samples after 72 hours of incubation with drugs: median. First
(Q1) and third (Q3) quartiles.
Patients’ samples                                                 EC50 (µM)                                                                         Emax (% Survival)
Drugs                                    Median                         Q1                       Q3                         Median                        Q1                                 Q3 
Panobinostat                                  0.008                              0.002                        0.024                                  3.3                                  0.0                                         7.5
Bortezomib                                     0.033                              0.002                        0.056                                  6.4                                  1.9                                       11.0
Prednisolone                                 0.144                              0.079                        0.286                                 26.0                                24.6                                      28.6
HSP990                                             0.041                              0.029                        0.048                                 39.9                                16.6                                      43.7
BKM120                                           0.893                              0.866                        0.964                                 28.3                                25.8                                      34.4
Ponatinib                                         1.716                              1.317                        3.341                                  0.0                                  0.0                                         0.0
Pomalidomide                                1.961                              1.961                        1.961                                 72.1                                72.1                                      72.1
Anagrelide                                      3.518                              2.528                        6.787                                 45.8                                38.3                                      51.7
Bosutinib                                        4.517                              2.674                        9.740                                  0.0                                  0.0                                         0.0
Nilotinib                                          5.996                              4.804                        9.651                                  2.5                                  0.0                                       10.3
Danazol                                            9.220                              8.026                       10.414                                45.4                                39.6                                      51.3
Sorafenib                                       10.272                            10.164                      10.897                                 0.0                                  0.0                                         0.3
Everolimus                                    22.606                            17.676                      25.872                                 0.0                                  0.0                                         0.0
SB431542                                        27.334                            16.362                      38.307                                 0.0                                  0.0                                         0.0
regression was performed for the correlation of time of response
with ex vivo activity of ruxolitinib. For the statistical analysis of
phospho-kinase array, an ANOVA test was performed. A t-test
was used to assess whether the CI of each combination was sig-
nificantly synergistic. For collagen expression assays and phospho-
proteomics studies, Student t-test was used when the populations
were normal and the non-parametric Wilcocox t-test when they
were not. P<0.05 was considered statistically significant. Statistical
analyses were performed with GraphPad Prism v.6.00 for
Windows (GraphPad Software, La Jolla, CA, USA) or STATA v.13
(StataCorp., College Station, TX, USA).
Results
Ruxolitinib activity in cell lines and patients’ samples
We first evaluated the activity of ruxolitinib in 
JAK2-mutated cell lines. Ruxolitinib efficiently inhibited
the viability of BA/F3 and SET2 V617F JAK2 cells with an
EC50 of 35 nM and 25 nM, respectively (Online
Supplementary Figure S1A). The EC50 for ruxolitinib in
BA/F3 WT cells was 212 nM, indicating the importance of
the JAK2-V617F mutation for the activity of ruxolitinib.
Nonetheless, when we compared the activity of ruxoli-
tinib in patients' PBMCs with or without a JAK2 muta-
tion, using ex vivo model A, we found that its activity was
not significantly different, with an EC50 of 55 nM. For this
reason, subgroups based on the mutation in JAK2 were
not studied further. 
To determine the best cell model to screen drugs in com-
bination with ruxolititinb, its activity was tested in the
two different ex vivo culture models. The only method that
provided a sufficient number of cells for screening was
model B, although the EC50 for ruxolititinb using this
model was 0.747 µM. Greater ruxolitinib activity was
found when PBMCs were seeded in methylcellulose in the
presence of ruxolitinib (model A: EC50 = 43 nM) (Online
Supplementary Table S4 and Online Supplementary Figure
S1B). Moreover, if ex vivo activity of ruxolitinib was com-
pared with the time of response to ruxolitinib of each
patient sample, it was found that both models A and B
distinguished patients' samples with responses >6 months
(Online Supplementary Figure S1C). 
BCR/ABL or ABL kinase inhibitors and PDGFR and
TGFβR inhibitors are effective combinations with 
ruxolitinib in cell lines and patients' samples
To examine the best combination with ruxolitinib,
dose-response curves of all tested drugs in monotherapy
or in combination with ruxolitinib were first analyzed in
BA/F3 V617F JAK2 cells using an automated flow cytom-
etry platform. Drugs exhibiting the best behavior in the
presence of ruxolitinib were then selected to perform the
same assay using PBMCs of MF patients  in ex vivo model
B. Drugs with more activity in the screening were also
included in dose-response assays in monotherapy with
patients' samples.
Results showed that the BCR/ABL or SRC/ABL tyrosine
kinase inhibitors (TKI) nilotinib and bosutinib, respective-
ly, together with danazol, a synthetic androgen reported
to reverse anemia,23 and SB432542, an inhibitor of the
TGF-β receptor related to the fibrogenic processes, were
among the four best combinations in BA/F3 JAK2 V617F
cells (Figure 1A). Accordingly, they presented the lowest
increments between their EC50 in the presence or absence
of ruxolitinib (ΔEC50 nilotinib = -92.4%; ΔEC50 bosutinib =
-87.7%; ΔEC50 danazol = -80.1%; ΔEC50 SB432542 = 
-77.1%). When tested in patients' samples, of the two
BCR/ABL inhibitors, only nilotinib showed a lower EC50
in the presence of ruxolitinib than in its absence (ΔEC50
nilotinib = -21.6%), together with SB432542 (ΔEC50 = 
-11.7%) (Figure 1B). 
Online Supplementary Table S5 shows the drugs listed by
their Emax and EC50. The most active drugs in BA/F3 JAK2
V617F cells were the histone deacetylase HDAC6
inhibitor panobinostat (EC50 = 0.041mM), the proteasome
inhibitor bortezomib (EC50 = 0.041 mM), and the
immunomodulatory HSP90 inhibitor HSP990 (EC50 =
A.A. Cortés et al.
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Figure 1. Effect of each drug in combination with 100 nM ruxolitinib in BA/F3 JAK2-V617F3 cell line (A) or in patients' peripheral blood mononuclear cells (B).
y-axis: the increment between the EC50 for each drug in the presence of ruxolitinib minus its EC50 in monotherapy. Results are expressed as the mean±Standard
Deviation (SD) of 2 independent experiments in cell lines (A) and median and interquartile range in patients' samples (B).
A B
0.045 mM). Interestingly, these inhibitors were also the
most active drugs in patients' samples (Table 2), showing
an EC50 of 0.008 mM, 0.033 mM and 0.041 mM, respective-
ly. Furthermore, prednisone, an immunosuppressant used
to control symptoms of MF by decreasing the levels of
cytokines and growth factors such as TGF-β,24 showed an
EC50 of 0.144 mM. Other active drugs in the low micromo-
lar range included the signaling pathway inhibitors
BKM120 (EC50 = 3.331 mM) and ponatinib (EC50 = 5.530
mM) (Online Supplementary Table S5). Patients' PBMCs
were even more sensitive to these drugs: EC50 BKM120 =
0.893 mM, EC50 ponatinib = 1.716 mM (Table 2). 
Curiously, drugs used in treatment of MF such as dana-
zol or prednisone did not have any effect on BA/F3 JAK2
V617F viability (Online Supplementary Table S5), but pred-
nisone was effective in combination with ruxolitinib
(ΔEC50 = -13.9%) (Figure 1A). Patients' samples showed
the same response (ΔEC50 = -18.0%) (Figure 1B). 
Ruxolitinib/nilotinb/prednisone combination has a
synergistic effect on myeloid cell lines and patient
peripheral blood mononuclear cells 
Given the synergistic effect of nilotinib with ruxolitinib
in BA/F3 JAK2 V617F cells, we next studied the effect of
adding prednisone to this combination in myeloid cell
lines and patients' PBMCs. As well as being a potent
BCR/ABL TKI, nilotinib has been reported to inhibit the
PDGF receptor, which is involved in fibrogenesis.20  
A synergistic effect with all combinations of the three
drugs tested was found in BA/F3 JAK2 V617F and SET2
cells (Table 3). By contrast, only four of the eight doses
tested were synergistic in BA/F3 wild-type (WT) cells,
again suggesting an important role for the V617F mutation
in the activity of the drug combination. We repeated this
assay using monotherapy or combination regimens in
model A cultures (PBMCs) to test the effect of the combi-
nations in myeloid progenitors. Myelofibrosis patients'
samples were sensitive to nilotinib and prednisone with
an EC50 of 6.6 mM and 13.1 mM, respectively. Moreover,
all combinations tested (ruxolitinib/nilotinib and ruxoli-
tinib/niloitnib/prednisone) exhibited synergic behavior in
at least two of the five patients' samples tested. In addi-
tion, the combination of 160 nM ruxolitinib, 8 mM nilo-
tinib and 0.8 mM prednisone was synergistic in all the
patients' samples tested (Table 4).  
Ruxolitinib/nilotinb/prednisone combination blocks
JAK/STAT and MAPK signaling 
The signaling pathways affected by the ruxolitinib/nilo-
tinib/prednisone combination or monotherapy were next
characterized in SET2 cells using the Proteome ProfilerTM
phosphoprotein array after treatment for 30 min. Results
showed that, among others, phosphorylation of STAT5
was significantly inhibited 88.94%, TOR 76.55%, ERK
87.55%, and SRC 76.88% (Figure 2) by drug combination
(ANOVA ***P<0.005). Western blotting confirmed that the
phosphorylation of STAT5 and ERK was inhibited by rux-
olitinib in monotherapy by 69.8±8.1% and 87.7±2.3%,
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Figure 2. Screening for signaling proteins affected by 32 nM ruxolitinib (R), 1.6 µM nilotinib (N), 0.8 mM prednisone (P), and their combinations, using a phospho-
protein array. C: Control. The SET2 cell line was incubated with R, N, P or their combination for 48 hours and phosphoprotein analysis was performed.
respectively. In combination with nilotinib and pred-
nisone, STAT5 and ERK were inhibited by 69.2±11.8%
and 29.4±4.5%, respectively (Figure 3A and B). By con-
trast, phosphorylation of AKT was not inhibited in any
case (data not shown). 
Ruxolitinib/nilotinib/prednisone combination 
decreases the synthesis of collagen I in bone marrow
mesenchymal cells
Myelofibrosis is characterized by an increase in collagen
deposition, among other fibrillar proteins, in BM, which
prevents its proper functioning. To study the effect of rux-
olitinib, nilotinib and prednisone (in monotherapy and in
combination), on collagen expression, we utilized the
HS27a mesenchymal cell line, together with TGF-β as an
inductor of collagen expression. TGF-β increased the
expression of COL1A1 200.9% over untreated cells
(Figure 4A). Nilotinib decreased the mRNA expression of
COL1A1 in HS27a cells by 60.2±0.9% in monotherapy,
by 51.9±2.9% in combination with ruxolitinib and
62.2±1.9% in combination with ruxolitinib and pred-
nisone. As a complementary test, we measured collagen
expression by immunocytochemistry, finding that colla-
gen synthesis was reduced, especially in monotherapy
(79.13±20.5%) and in combination with ruxolitinib
(79.20±2.3%) (Figure 4B and Online Supplementary Figure
S2). 
Discussion
The management of MF remains challenging, even in
the era of TKIs and personalized medicine. The discovery
of the V617F mutation in JAK2 as a physiopathogenic
mechanism of MPN3-7 prompted the development of
JAK2 inhibitors and represented a revolution in the treat-
ment of MF. Currently, the only approved JAK2 inhibitor
for the treatment of MF and PV in the second-line is rux-
olitinib,25 which has been shown to be effective in reduc-
ing hepatosplenomegaly, resolving disease-related symp-
toms, and producing a significant increase in overall sur-
vival when compared with conventional therapies.26
Nevertheless, there are some limitations to the use of rux-
olitinib, including hematologic toxicity (anemia and
thrombocytopenia) and a failure to achieve histopatholog-
ical and molecular complete responses.15 Accordingly, the
A.A. Cortés et al.
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Table 3. Combination Index of ruxolitinib (R), nilotinib (N) and prednisone (P) in samples of cell lines. SET2: BA/F3 JAK2 wt or V617F cell lines
were incubated with R, N, P or their combination for 48 hours and then Wst8 was performed. 
                                                                                                              BAF3 JAK2 V617F                                        BAF3 JAK2 wt       
Ruxolitinib (nM)        Nilotinib (mM)          Prednisone (mM)        CI Mean           SEM                    P             CI Mean         CI SEM           P                
6.4                                              320                                                                    >2                    9.47                                                NA                                                                 
6.4                                               1.6                                                                     >2                    3.35                                                NA                                                                 
32                                               0.32                                                                   >2                   12.49                                              NA                                                                 
32                                                1.6                                                                     >2                  187.51                                             NA                                                                 
6.4                                              0.32                                   0.16                         0.067                  0.02                         *                     NA                                                                 
6.4                                              0.32                                    0.8                           0.198                  0.12                        **                    NA                                                                 
6.4                                               1.6                                    0.16                          0.082                  0.03                       ***                 0.311                 0.192                                       
6.4                                               1.6                                     0.8                           0.095                  0.03                       ***                 0.172                 0.090                                       
32                                               0.32                                   0.16                         0.049                  0.02                       ***                   NA                                                                 
32                                               0.32                                    0.8                           0.040                  0.01                       ***                 0.198                 0.086               **                  
32                                                1.6                                    0.16                         0.051                  0.01                       ***                   NA                                                                 
32                                                1.6                                     0.8                           0.063                  0.01                      ***                0.248                 0.060              **                 
                                                                                                                       SET2                                                                              
Ruxolitinib (nM)        Nilotinib (mM)          Prednisone (mM)        CI Mean           SEM                    P                                                                          
32                                                1.6                                                                  0.815                0.261                                                                                                                        
32                                                 8                                                                    0.596                 0.189                                                                                                                        
160                                              1.6                                                                  1.374                0.144                                                                                                                        
160                                               8                                                                   0.857                0.109                                                                                                                        
32                                                1.6                                    0.16                         0.538                 0.162                                                                                                                        
32                                                1.6                                     0.8                           0.448                 0.057                                                                                                                        
32                                                 8                                      0.16                         0.396                 0.089                        *                                                                                             
32                                                 8                                       0.8                           0.337                 0.040                        *                                                                                             
160                                              1.6                                    0.16                         0.155                 0.015                      ***                                                                                           
160                                              1.6                                     0.8                           0.158                 0.010                      ***                                                                                           
160                                               8                                      0.16                         0.173                 0.011                     ***                                                                                          
160                                               8                                       0.8                           0.153                 0.011                     ***                                                                                          
NA: drugs combination with an effect less than of 20% compared to control. Combination Index (CI) < 0.9 indicates synergy (Italic); CI > 1.1 indicates antagonism (Italic Bold);
CI from 0.9 to 1.1 indicates additivity (Bold). *P<0.05; **P<0.01; ***P<0.001.
unmet clinical need to increase the effectiveness of the
treatment and decrease its toxicity guides the search for
combination treatments with ruxolitinib.
The main objective of this work was to evaluate the
best combination of drugs for the treatment of MF, main-
taining ruxolitinib as a therapeutic base and reducing its
toxicity while maintaining its efficacy. Since MF is not
characterized by large amounts of pathological cells, as
in acute myeloid leukemia,27 it is challenging to develop
an ex vivo model to screen 17 combinations.
Consequently, we elected to utilize myeloid cells
obtained from 14-day old cultures of PBMCs in methyl-
cellulose (ex vivo model B), which produce a sufficient
supply of cells for screening. Interestingly, the most
active drugs in monotherapy coincided with the most
active drugs in preclinical trials, including bortezomib,28
panobinostat29 and HSP990.30 Therefore, the search for
combination treatments with ruxolitinib is in response to
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Figure 3. Effect of 32 nM ruxolitinib (R), 1.6 µM nilotinib (N), 0.8 mM prednisone (P), and their combinations, on the phosphorylation of ERK1/2 and STAT5 in cell
lines. Results are expressed as the mean±Standard Error of Mean. Data are representative of at least 2 separate experiments. *P<0.05; **P<0.01; ***P<0.001.
C: control.
Table 4. Combination Index (CI) of ruxolitinib (R), nilotinib (N) and prednisone (P) in samples of myelofibrosis (MF) patients and healthy donors.
Mononuclear cells from peripheral blood of MF patients and healthy donors were seeded at 200,000-500,000 cell/mL in Metocult supplement-
ed with SCF and IL3 in presence of drugs for two weeks. Then flow cytometry analysis was performed.  
Drugs                                                                                                                          MF                                                  Healthy donors
Ruxolitinib (nM)      Nilotinib (mM)       Prednisone (mM)         P20          P33            P27               P19              P34              C1                   C3
32                                             1.6                                                               >2          0.50               1.09                   0.40                 0.22                 0.24                      0.20
32                                               8                                                                1.44           0.18               0.30                   0.34                 0.55                 0.12                      0.13
160                                           1.6                                                               1.83          1.05              0.32                   0.20                 0.16                 0.30                      >2
160                                             8                                                                 1.55            0.4                0.22                   0.20                 0.05                 0.21                      0.13
32                                             1.6                                  0.8                          >2          >2                0.36                   0.43                 0.10                 >2                  >2
32                                             1.6                                   4                           >2          >2                0.15                   0.24                   -                   0.53                      >2
160                                             8                                   0.8                         0.31            0.64               0.20                   0.10                 0.02                 0.48                      >2
160                                             8                                     4                           0.39             >2                0.13                   0.18                   -                   0.54                      >2
CI < 0.9 indicates sinergy (Italic); CI > n 1.1 indicates antagonism (Italic Bold).  P<0.05 is considered significative.
A
B
the need to increase the effectiveness of the treatment and
decrease its toxicity. 
We found that the best combinations were those with
BCR/ABL inhibitors, nilotinib and bosutinib, used for the
treatment of chronic myeloid leukemia (CML).31
Nevertheless, TKIs such as perifosine or BKM120, corticos-
teroids such as prednisone, androgens such as danazol, and
the TGF-β receptor inhibitor SB431542, also decreased the
EC50 in combination with ruxolitinib. It is interesting to
note that some of these combinations have already been
tested in clinical trials, such as ruxolitinib plus danazol (clin-
icaltrials.gov identifier: 01732445);18 this study showed that
while there was no improvement in  hematologic
response, stabilization of the patients was achieved.
Regarding ruxolitinib plus BKM120 (clinicaltrials.gov identifi-
er: 01730248), although no results have yet been reported,
preliminary analyses (ASH 2015) are not encouraging.
Interestingly, it has previously been described that the
combination nilotinib plus ruxolitinib can eliminate CD34+
leukemic progenitors in CML32 and Philadelphia chromo-
some positive acute lymphoblastic leukemia;33 however, it
was not known whether this also holds for MF. We show
here  synergistic behavior of nilotinib plus ruxolitinib,
which blocks colony formation in clonogenic assays with
patients' PMBCs, and inhibits the phosphorylation of both
STAT5 and ERK 1/2. Furthermore, the inclusion of pred-
nisone is key to achieve synergy in the survival assays of
cell lines and increases the power of synergy in patients'
samples. In addition, this combination inhibited the syn-
thesis of collagen in BM mesenchymal cells, which is
important to achieve histopathological response. The
antifibrogenic effect of nilotinib has been previously
described in skin cells,20,34 liver35 and muscle,36 via its ability
to inhibit the PDGF receptor, which is directly involved in
the induction of collagen synthesis. In addition, ruxolitinib
is able to stabilize, or even ameliorate, fibrosis through its
ability to reduce the proinflamatory state, which is typical
in MF.37 Similar results are seen with corticosteroids like
prednisone, which decreases the levels of cytokines and
proinflammatory growth factors including TGF-β.24 
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Figure 4. Effect of ruxolitinib (R),
nilotinib (N), prednisone (P), and
their combination, on collagen I
mRNA expression using quantita-
tive polymerase chain reaction  or
protein expression by immunocy-
tochemistry. HS27a cell line was
incubated with R, N, P or their com-
bination for 1 hour (h) and then for
24 h with 2 ng/mL TGF-β. Results
were expressed as the
mean±Standard Error of Mean.





Our results indicate that the combination ruxolitinib,
nilotinib and prednisone would eliminate more efficiently
pathological cells, stopping and/or reverting MF. It must be
remembered, however, that this evidence was obtained in
vitro and the impact on the clinical situation still needs to
be proved. With this is mind, and given that all the drugs
are approved for clinical practice, we have recently initiat-
ed a clinical trial (the RuNic Trial; clinicaltrials.gov identifier:
02973711) which does not require an in vivo analysis in
animal models.
In summary, MF is a complex disease in which alter-
ations in tyrosine kinase-related signaling participates in
the amplification of hematopoietic clones and in the
increased production of cytokines and growth factors by
pathological cell clones, which stimulates MF.38 It is often
advantageous to use combinations of drugs that target dif-
ferent pathways involved in the pathophysiology of a dis-
ease, shown here with the objective of decreasing fibrosis
of the BM, and not only eradicating the tumor clone, as
previously attempted.15,30,39,40 Our results lead us to hypoth-
esize that the combination therapy ruxolitinib and pred-
nisone might provide a dampened proinflammatory envi-
ronment and nilotinib would block fibrosis. Accordingly,
the combination ruxolitinib/nilotinib/prednisone is con-
figured as a therapeutic strategy against MF that aims to
enhance the effect of ruxolitinib, and promote the reduc-
tion of fibrosis in the BM and reduce inflammation. As
mentioned above, this combination will be studied in a
phase Ib/II clinical trial in MF (the RuNic Trial;  clinicaltri-
als.gov identifier: 02973711).
Further information is available in the Online
Supplementary Appendix.  
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